Form 4: HeartSciences Director Granted 15,000 RSUs

HeartSciences Inc. Director Bruce Bent received a grant of 15,000 Restricted Stock Units, subject to vesting conditions including shareholder approval, time-based milestones, and performance targets.

Summary

• Bruce Bent, a Director of HeartSciences Inc. (HSCS), was granted 15,000 Restricted Stock Units (RSUs).
• The RSUs were granted under the Issuer's 2023 Equity Incentive Plan, as amended, following approval by the Issuer's board of directors.
• Each vested RSU will convert into one share of the Issuer's common stock ($0.001 par value per share).
• Vesting is subject to two primary conditions: (i) shareholder approval of any amendment or modification to the Plan, and (ii) time-based vesting.
• Time-based vesting dictates that 50% of the RSUs vest on the one-year anniversary of the grant date, and thereafter, 1/8th of the RSUs vest on each subsequent quarterly anniversary, leading to full vesting on the two-year anniversary of the grant date, provided continuous service on the Board.
• Accelerated vesting of 100% of the RSUs will occur upon a Change of Control (as defined in the Plan) or if the Issuer achieves $250,000 or more of revenue in any fiscal quarter ending after the grant date.

Sentiment

Score: 6

Explanation: The grant of RSUs to a director is generally a neutral to slightly positive event, as it aligns the director's incentives with the company's long-term performance and shareholder value, without indicating immediate financial results.

Positives

• The RSU grant aligns the Director's interests with those of shareholders by tying compensation to company performance and long-term service.
• The performance-based vesting condition (achieving $250,000 in quarterly revenue) incentivizes management to drive revenue growth.

Negatives

• Potential future dilution for existing shareholders if all 15,000 RSUs vest and convert into common stock.

Risks

• The RSUs may not vest if the Issuer's shareholders do not approve the necessary amendment or modification to the 2023 Equity Incentive Plan.
• The RSUs may not fully vest if the Reporting Person does not continuously serve on the Board through each applicable Vesting Date.
• The accelerated vesting condition tied to $250,000 quarterly revenue may not be met, impacting the timing of full vesting.

Future Outlook

The RSU grant includes performance-based vesting tied to achieving $250,000 or more in revenue in any fiscal quarter, indicating a future focus on revenue growth. The time-based vesting schedule extends over two years, suggesting a long-term commitment for the director.

Industry Context

The grant of Restricted Stock Units is a common practice in the life sciences and technology sectors, such as HeartSciences Inc., to attract, retain, and incentivize directors and key personnel. It aligns their long-term interests with shareholder value creation, particularly in growth-oriented companies where cash compensation may be limited.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential future dilution from RSU conversion, but also benefit from aligned director incentives and potential for accelerated vesting based on revenue growth.
• Director (Bruce Bent): Receives equity compensation, incentivizing long-term service and performance aligned with company goals.

Next Steps

• Shareholder approval of the amendment or modification to the Issuer's 2023 Equity Incentive Plan will be required for the RSUs to vest.
• The Reporting Person must continue to serve on the Board through the specified vesting dates for the time-based vesting to occur.
• The company will aim to achieve $250,000 or more in revenue in a fiscal quarter to trigger accelerated vesting.

Key Dates

Keywords

HeartSciences Inc., HSCS, Restricted Stock Units, RSU, Equity Incentive Plan, Director Compensation, Stock Grant, Vesting Conditions, Corporate Governance